Study on the Safety and Effects of TNG908 in Patients with Advanced or Metastatic Solid Tumors Missing the MTAP Gene

2 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a new treatment called TNG908 for patients with certain types of advanced or metastatic solid tumors. These tumors have a specific genetic change known as MTAP deletion. The study includes various types of cancers such as non-small cell lung cancer, mesothelioma, sarcoma, pancreatic cancer, and a type of brain cancer called glioblastoma multiforme. The purpose of the study is to evaluate the safety and initial effectiveness of TNG908 in treating these cancers.

The study is divided into two phases. In the first phase, different doses of TNG908 will be tested to determine the safest and most effective dose. In the second phase, the focus will be on assessing how well TNG908 works in shrinking the tumors. Participants will take TNG908 in the form of a film-coated tablet, which is taken orally. Some participants may receive a placebo, which looks like the real medication but does not contain the active ingredient.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study aims to gather important information about the potential benefits and risks of TNG908 for treating these specific types of cancer. The trial is expected to continue until September 2025, providing valuable insights into the treatment of MTAP-deleted tumors.

1 joining the study

Upon joining the study, the patient will be informed about the trial’s purpose and procedures. The patient must provide written informed consent, confirming understanding and agreement to participate in the study.

2 initial assessment

The patient will undergo an initial assessment to confirm eligibility. This includes verifying the presence of a specific genetic deletion in the tumor, known as MTAP-deletion, and ensuring adequate organ function through laboratory tests.

3 treatment phase 1

The patient will begin treatment with TNG908, administered as a film-coated tablet for oral use. The dosage will be determined based on the study’s requirements to find the maximum tolerated dose (MTD).

The patient will be monitored for any dose-limiting toxicities (DLTs) during the first 28 days of treatment.

4 treatment phase 2

In phase 2, the patient will continue receiving TNG908 to assess its anti-tumor activity. The treatment aims to evaluate the overall response rate (ORR) and duration of response (DOR) in patients with advanced solid tumors.

The patient’s progress will be assessed using specific criteria to measure tumor response.

5 monitoring and follow-up

Throughout the study, the patient will undergo regular monitoring to assess the type, frequency, and severity of any side effects. This includes changes in vital signs, laboratory tests, and performance status.

Pharmacokinetic parameters of TNG908 will be evaluated to understand how the drug is processed in the body.

6 study completion

The study is estimated to end by September 2025. Upon completion, the patient will have a final assessment to evaluate the overall impact of the treatment on their condition.

Who Can Join the Study?

  • Must be at least 18 years old at the time of signing the main study consent form.
  • Must have a good general health status, which is measured by specific performance scores:
    • For patients with solid tumors other than a specific type of brain tumor called R/R GBM, a score of 0 to 1 on the ECOG scale is required. This scale measures how well a person can perform daily activities.
    • For patients with R/R GBM, a score of 70 or higher on the Karnofsky scale is needed. This scale also measures the ability to carry out daily activities.
  • Must have a confirmed diagnosis of a locally advanced, metastatic, or unresectable solid tumor, or for those with R/R GBM, must have this specific type of brain tumor.
  • Must have received standard treatment options that are available for their condition.
  • Must have a specific genetic change in their tumor called a bi-allelic (homozygous) deletion of MTAP, which can be detected by certain tests.
  • Must have adequate organ function, which means the organs are working well enough, as shown by local lab tests.
  • Must have adequate liver function, as shown by local lab tests.
  • Must have adequate kidney function, as shown by local lab tests.
  • If female, must have a negative pregnancy test result at the time of screening.
  • Must be able to swallow tablets.
  • Must provide written informed consent, which means agreeing to participate in the study after being fully informed about it, according to local guidelines.

Who Cannot Join the Study?

  • Patients who have not been diagnosed with locally advanced or metastatic MTAP-deleted solid tumors. Locally advanced means the cancer has spread from where it started to nearby tissue or lymph nodes. Metastatic means the cancer has spread to other parts of the body. MTAP-deleted refers to a specific genetic change in the tumor.
  • Patients who do not have MTAP-deleted relapsed or refractory Grade 4 astrocytoma or glioblastoma multiforme. Relapsed means the cancer has returned after treatment. Refractory means the cancer does not respond to treatment.
  • Patients who do not have locally advanced or metastatic MTAP-deleted squamous or nonsquamous NSCLC. NSCLC stands for non-small cell lung cancer, which is a type of lung cancer.
  • Patients who do not have locally advanced or metastatic MTAP-deleted mesothelioma. Mesothelioma is a type of cancer that affects the lining of the lungs or abdomen.
  • Patients who do not have locally advanced or metastatic MTAP-deleted sarcoma. Sarcoma is a type of cancer that begins in the bones or soft tissues.
  • Patients who do not have locally advanced or metastatic MTAP-deleted pancreatic ductal adenocarcinoma or adenosquamous carcinoma with predominantly adenocarcinoma histology. These are types of pancreatic cancer.
  • Patients who do not have other locally advanced or metastatic MTAP-deleted solid tumors.
  • Patients who do not have MTAP-deleted relapsed or refractory glioblastoma multiforme.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Institut Gustave Roussy Villejuif France
Oncopole Claudius Regaud Toulouse France

Other Sites

Site Name City Country Status
Institut de Cancérologie de l’Ouest Saint-Herblain France
Clegwf Lzra Beotfq Lyon France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
15.12.2022

Trial locations

TNG908 is an investigational medication being studied for its potential to treat advanced or metastatic solid tumors that have a specific genetic deletion known as MTAP-deletion. The trial aims to evaluate the safety and tolerability of this medication, as well as its preliminary effectiveness in reducing tumor size or slowing tumor growth in affected patients.

Astrocytoma – Astrocytoma is a type of brain tumor that originates from star-shaped brain cells called astrocytes. It can vary in its growth rate, with some forms being slow-growing and others more aggressive. As the tumor grows, it can cause symptoms such as headaches, seizures, and changes in behavior or personality. The tumor may infiltrate surrounding brain tissue, making it challenging to remove completely. Over time, it can lead to increased pressure within the skull, affecting brain function.

Glioblastoma Multiforme – Glioblastoma multiforme is an aggressive type of cancer that occurs in the brain or spinal cord. It arises from astrocytes, the supportive tissue of the brain, and is known for its rapid growth and tendency to invade nearby brain tissue. Symptoms often include headaches, nausea, vomiting, and neurological deficits such as weakness or speech difficulties. The tumor’s location and size can significantly impact the severity of symptoms. It is characterized by its heterogeneous appearance and necrotic areas within the tumor.

Non-Small Cell Lung Cancer (NSCLC) – Non-small cell lung cancer is the most common type of lung cancer, accounting for a majority of cases. It typically grows and spreads more slowly than small cell lung cancer. Symptoms may include a persistent cough, chest pain, and shortness of breath. As the disease progresses, it can spread to other parts of the body, such as the bones or brain. The cancer is often associated with a history of smoking, although non-smokers can also develop it.

Mesothelioma – Mesothelioma is a rare cancer that affects the lining of the lungs, abdomen, or heart. It is primarily caused by exposure to asbestos fibers. Symptoms can include chest pain, shortness of breath, and abdominal swelling. The disease tends to develop slowly, often taking decades after exposure to asbestos to appear. As it progresses, it can lead to significant respiratory or digestive issues.

Sarcoma – Sarcoma is a type of cancer that originates in the bones and soft tissues, such as fat, muscle, and blood vessels. It can occur anywhere in the body and is known for its diverse forms and behaviors. Symptoms depend on the tumor’s location and may include a noticeable lump, pain, or swelling. Sarcomas can grow and spread to other parts of the body, complicating treatment. They are relatively rare compared to other types of cancer.

Pancreatic Ductal Adenocarcinoma – Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer, originating in the ducts of the pancreas. It is known for its aggressive nature and tendency to spread quickly to nearby organs. Symptoms often include jaundice, weight loss, and abdominal pain. The cancer can obstruct the bile duct, leading to digestive issues. Its location deep within the abdomen makes early detection challenging.

Trial ID:
2024-511976-34-00
Protocol code:
TNG908-C101
NCT ID:
NCT05275478
Trial Phase:
Phase I and Phase II (Integrated) – First administration to humans

Other Trials to Consider

  • Study on the Safety and Effectiveness of C1 Esterase Inhibitor and Sodium Chloride for Patients with Aneurysmal Subarachnoid Hemorrhage

    Recruiting

    2 1 1
    Investigated diseases:
    The Netherlands
  • Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

    Recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain